Tg54531 is a transgenic mouse with transmembrane human TNF deregulated expression resulting in the spontaneous development of arthritis pathology that closely resembles human rheumatoid arthritis.

The mice develop arthritis with 100% penetrance and provide a fast in-vivo model for evaluating human therapeutics targeting rheumatoid arthritis.

The Tg5453 mouse model was successfully used in establishing the therapeutic efficacy of Remicade®, the first anti-TNF therapeutic to be successfully applied in the clinic, and is currently used for screening anti-rheumatoid candidate drugs.

Representative graph of the progression of the in vivo arthritic score in Tg5453 animals untreated or treated with commercially available anti-hTNF therapeutics.


 Download the whitepaper to learn more on:

  • The disease model
  • Study design
  • Routes of administration
  • Validation data
  • Readouts
  • Analysis options